Upstream Bio (UPB) Capital Expenditures (2024 - 2025)
Upstream Bio (UPB) posted quarterly Capital Expenditures of $110000.0 for Q4 2025, down 70.9% year-over-year from $378000.0 in Q4 2024, and up 1275.0% quarter-over-quarter from $8000.0 in Q3 2025.
Powered by 
Analysis
Upstream Bio (UPB) Capital Expenditures (2024 - 2025) Analysis & Trends
Upstream Bio's Capital Expenditures history runs 2 years deep, the most recent figure standing at $110000.0 for Q4 2025.
- In Q4 2025, Capital Expenditures fell 70.9% year-over-year to $110000.0; the TTM figure through Dec 2025 stood at $496000.0 (changed N/A YoY), while the FY2025 annual figure was $165000.0, down 67.71% from the prior year.
- Capital Expenditures for Q4 2025 stood at $110000.0, up from $8000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $378000.0 in Q4 2024, with the low at $8000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Upstream Bio | 327.95 Mn | 327.95 Mn | -3.29 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 54,000.00 |
| Sep 30, 2025 | 64,000.00 |
| Dec 31, 2024 | 185,000.00 |